Cencora, Inc. (NYSE:COR) Shares Bought by Cambridge Investment Research Advisors Inc.

Cambridge Investment Research Advisors Inc. boosted its stake in shares of Cencora, Inc. (NYSE:COR) by 65.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 55,648 shares of the company’s stock after buying an additional 22,013 shares during the quarter. Cambridge Investment Research Advisors Inc.’s holdings in Cencora were worth $12,538,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of COR. Rise Advisors LLC acquired a new stake in shares of Cencora in the first quarter valued at approximately $25,000. New Millennium Group LLC acquired a new stake in shares of Cencora in the second quarter valued at approximately $26,000. Legacy Bridge LLC acquired a new stake in shares of Cencora in the first quarter valued at approximately $27,000. TCTC Holdings LLC acquired a new stake in shares of Cencora in the first quarter valued at approximately $29,000. Finally, TFO Wealth Partners LLC purchased a new position in shares of Cencora during the first quarter valued at approximately $30,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Cencora news, CEO Steven H. Collis sold 10,755 shares of the firm’s stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $222.12, for a total transaction of $2,388,900.60. Following the completion of the transaction, the chief executive officer now directly owns 285,088 shares of the company’s stock, valued at approximately $63,323,746.56. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, CEO Steven H. Collis sold 10,755 shares of Cencora stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $222.12, for a total value of $2,388,900.60. Following the completion of the transaction, the chief executive officer now directly owns 285,088 shares of the company’s stock, valued at approximately $63,323,746.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Gina Clark sold 1,874 shares of Cencora stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $223.86, for a total transaction of $419,513.64. Following the completion of the transaction, the executive vice president now directly owns 13,284 shares of the company’s stock, valued at $2,973,756.24. The disclosure for this sale can be found here. Insiders sold a total of 4,479,366 shares of company stock valued at $1,076,666,297 in the last ninety days. Corporate insiders own 15.80% of the company’s stock.

Cencora Trading Down 0.4 %

Shares of COR stock traded down $0.94 during mid-day trading on Tuesday, reaching $233.50. The company’s stock had a trading volume of 1,290,234 shares, compared to its average volume of 1,368,015. The company’s 50 day simple moving average is $231.84 and its 200-day simple moving average is $232.79. Cencora, Inc. has a 12-month low of $171.65 and a 12-month high of $247.66. The company has a quick ratio of 0.53, a current ratio of 0.89 and a debt-to-equity ratio of 3.93. The firm has a market capitalization of $46.57 billion, a PE ratio of 25.65, a price-to-earnings-growth ratio of 1.68 and a beta of 0.45.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, beating analysts’ consensus estimates of $3.18 by $0.16. The business had revenue of $74.20 billion during the quarter, compared to analyst estimates of $73.32 billion. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The business’s revenue was up 10.8% on a year-over-year basis. During the same period last year, the business earned $2.92 EPS. On average, research analysts predict that Cencora, Inc. will post 13.56 EPS for the current fiscal year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 9th were issued a dividend of $0.51 per share. This represents a $2.04 annualized dividend and a yield of 0.87%. The ex-dividend date of this dividend was Friday, August 9th. Cencora’s dividend payout ratio is currently 22.32%.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on COR. Leerink Partners reissued an “outperform” rating and set a $275.00 price objective on shares of Cencora in a research note on Thursday, June 27th. Citigroup upped their price objective on shares of Cencora from $265.00 to $280.00 and gave the company a “buy” rating in a research note on Tuesday, April 30th. Robert W. Baird upped their price objective on shares of Cencora from $285.00 to $287.00 and gave the company an “outperform” rating in a research note on Thursday, August 1st. JPMorgan Chase & Co. upped their price objective on shares of Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research note on Wednesday, August 21st. Finally, StockNews.com raised shares of Cencora from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 2nd. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $258.63.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.